Revolutionizing Diabetes Management: Breakthrough in Weight Loss Maintenance
An outpatient endoscopic procedure, duodenal mucosal resurfacing, shows promise in maintaining weight loss after stopping GLP-1 medications for type 2 diabetes, as shown in interim clinical trial results. The procedure, which is approved in Europe, might address the weight regain issue post-medication, a significant unmet need.
A new clinical trial suggests that an outpatient endoscopic procedure could be a game-changer for type 2 diabetes patients struggling with weight regain after discontinuing their GLP-1 medications. In the trial, patients who underwent duodenal mucosal resurfacing regained significantly less weight compared to those who had a sham procedure.
The trial's initial findings revealed that the treatment group maintained over 80% of their weight loss six months following the procedure. This minimally invasive procedure appears to offer a solution to the weight regain issue faced by many patients once they stop GLP-1 medications due to cost or side effects.
While approved for diabetes treatment in Europe, duodenal mucosal resurfacing is still experimental in the U.S. Further results from the 300-patient trial are expected soon, potentially paving the way for future regulatory approval.
(With inputs from agencies.)
Google News